JP6818215B2 - クモ毒ペプチド由来の神経保護剤 - Google Patents

クモ毒ペプチド由来の神経保護剤 Download PDF

Info

Publication number
JP6818215B2
JP6818215B2 JP2018502163A JP2018502163A JP6818215B2 JP 6818215 B2 JP6818215 B2 JP 6818215B2 JP 2018502163 A JP2018502163 A JP 2018502163A JP 2018502163 A JP2018502163 A JP 2018502163A JP 6818215 B2 JP6818215 B2 JP 6818215B2
Authority
JP
Japan
Prior art keywords
peptide
seq
hi1a
sequence
asic1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018502163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522555A5 (https=
JP2018522555A (ja
Inventor
グレン フレデリック キング
グレン フレデリック キング
ラクラン ダグラス ラッシュ
ラクラン ダグラス ラッシュ
アイリーン シャサーノン
アイリーン シャサーノン
ゴンザレス サンディー ステファニー ピネダ
ゴンザレス サンディー ステファニー ピネダ
ロバート エドワード ウィドップ
ロバート エドワード ウィドップ
クラウディア アン アイルランド
クラウディア アン アイルランド
Original Assignee
ザ ユニバーシティー オブ クイーンズランド
ザ ユニバーシティー オブ クイーンズランド
モナシュ ユニバーシティー
モナシュ ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902845A external-priority patent/AU2015902845A0/en
Application filed by ザ ユニバーシティー オブ クイーンズランド, ザ ユニバーシティー オブ クイーンズランド, モナシュ ユニバーシティー, モナシュ ユニバーシティー filed Critical ザ ユニバーシティー オブ クイーンズランド
Publication of JP2018522555A publication Critical patent/JP2018522555A/ja
Publication of JP2018522555A5 publication Critical patent/JP2018522555A5/ja
Application granted granted Critical
Publication of JP6818215B2 publication Critical patent/JP6818215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2018502163A 2015-07-17 2016-07-18 クモ毒ペプチド由来の神経保護剤 Active JP6818215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902845A AU2015902845A0 (en) 2015-07-17 ASIC1a modulators inspired by spider venom peptides
AU2015902845 2015-07-17
PCT/AU2016/050633 WO2017011863A1 (en) 2015-07-17 2016-07-18 Neuroprotective agents derived from spider venom peptides

Publications (3)

Publication Number Publication Date
JP2018522555A JP2018522555A (ja) 2018-08-16
JP2018522555A5 JP2018522555A5 (https=) 2019-08-22
JP6818215B2 true JP6818215B2 (ja) 2021-01-20

Family

ID=57833496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502163A Active JP6818215B2 (ja) 2015-07-17 2016-07-18 クモ毒ペプチド由来の神経保護剤

Country Status (5)

Country Link
US (2) US10485847B2 (https=)
EP (1) EP3325503A4 (https=)
JP (1) JP6818215B2 (https=)
AU (1) AU2016295423B2 (https=)
WO (1) WO2017011863A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485847B2 (en) 2015-07-17 2019-11-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides
CA3057881A1 (en) 2017-04-04 2018-10-11 Baylor University Targeted mosquitocidal toxins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
DE60112424T2 (de) * 2000-05-10 2006-05-24 Centre National De La Recherche Scientifique (Cnrs) Protonen-abhängiges na+-kanal hemmendes polypeptid
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
BRPI0605484A8 (pt) * 2006-11-21 2017-03-07 Fund Amparo Pesquisa Estado Minas Gerais Fapemig Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto
NZ727213A (en) * 2012-03-09 2020-03-27 Vestaron Corp Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
US10485847B2 (en) 2015-07-17 2019-11-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides

Also Published As

Publication number Publication date
AU2016295423B2 (en) 2020-09-03
US10485847B2 (en) 2019-11-26
US20200061156A1 (en) 2020-02-27
WO2017011863A1 (en) 2017-01-26
EP3325503A4 (en) 2019-03-27
US10881712B2 (en) 2021-01-05
EP3325503A1 (en) 2018-05-30
US20180207235A1 (en) 2018-07-26
JP2018522555A (ja) 2018-08-16
AU2016295423A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US9644011B2 (en) Mu-conotoxin peptides and use thereof as a local anesthetic
WO2019246071A1 (en) Fusion proteins comprising progranulin
US20110195909A1 (en) Novel x-conotoxin peptides (-ii)
JP6336979B2 (ja) α−コノトキシンペプチド、その医薬組成物及びそれらの使用
CN110799207A (zh) 缺少C5结合的Coversin变体
US20100120670A1 (en) Cyclised alpha-conotoxin peptides
RU2583299C2 (ru) Новые пептиды с анальгетическим эффектом, ингибирующие asic-rfyfks
JP6818215B2 (ja) クモ毒ペプチド由来の神経保護剤
CN107629114B (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
EP3169344B1 (en) Epha4 cyclic peptide antagonists for neuroprotection and neural repair
JP2020127419A (ja) 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
EP2225272B1 (en) Peptides derived from ncam (fgls)
WO2004099238A1 (en) NOVEL mu-CONOTOXIN PEPTIDES
CA2629376C (en) Inhibitors of parp activity and uses thereof
WO2009035417A1 (en) Neuroprotective agents
HK1164340A (en) Chi-conotoxin peptides (ii)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201204

R150 Certificate of patent or registration of utility model

Ref document number: 6818215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250